Volume 27, Number 8—August 2021
Research
Spotted Fever Group Rickettsioses in Israel, 2010–2019
Table 4
Laboratory features of 42 patients with spotted fever group rickettsiosis according to rickettsial species, during hospitalization days 1–3, Israel, 2010–2019*
Feature† | R. conorii Israeli tick typhus strain | R. conorii Malish strain | R. africae | New Rickettsia variant | Total | p value |
---|---|---|---|---|---|---|
No. cases |
33 |
2 |
4 |
3 |
42 |
|
Acute kidney injury (creatinine >1.3 mg/dL), no. (%) | 20/32 (62.5) | 0/2 | 1/4 (25) | 1/3 (33) | 22/41 (54) | NS‡ |
Creatinine, mg/dL, mean (range) |
1.8 (0.13–6.25) |
0.83 (0.7–0.9) |
0.96 (0.6–1.3) |
1.6 (1.17–2.4) |
1.6 (0.1–6.25) |
NS§ |
Hepatocellular injury pattern | ||||||
AST or ALT >2 ULN, no. (%) | 24/33 (73) | 2/2 (100) | 0/4 (100) | 2/3 (67) | 28/42 (67) | 0.02‡ |
AST, IU/L, mean (range) | 855 (42–8,895) | 249 (270–228) | 27 (23–31) | 83 (60–107) | 728 (23–8,895) | NS§ |
ALT, IU/L, mean (range) |
334 (12–2,881) |
94 (109–80) |
26 (25–29) |
88 (40–164) |
22/41 (54) |
NS§ |
Cholestatic injury pattern | ||||||
Alkaline phosphatase or GGT >2 ULN, no. (%) | 16/32 (48) | 2/2 (100) | 1/4 (25) | 2/3 (67) | 21/41 (51) | NS‡ |
Alkaline phosphatase, IU/L, mean (range) | 196 (32–1,056) | 109 (67–152) | 64 (63–65) | 265 (60–416) | 190 (32–1,056) | NS§ |
GGT, IU/L, mean (range) |
156 (15–1,026) |
150 (129–171) |
73 (21–125) |
507 |
154 (15–1,026) |
NS§ |
Jaundice, bilirubin >1.3 mg/dL, no. (%) | 14/33 (42) | 1/2 (50) | 0/3 | 0/3 | 15/41 (36) | NS‡ |
Bilirubin, mg/dL, mean (range) | 1.77 (0.29–10) | 2.6 (1.3–4) | 0.4 (0.3–0.5) | 0.93 (0.6–1.3) | 1.46 (0.29–10) | NS§ |
C-reactive protein >5 mg/L, no. (%) | 30/30 (100) | 1/1 (100) | 4/4 (100) | 3/3 (100) | 38/38 (100) | NS‡ |
C-reactive protein, mg/L, (range) |
207 (17–460) |
102 |
35 (17–61) |
223 (131–273) |
187 (17–410) |
0.034§ |
Rhabdomyolysis, creatine kinase >ULN, no. (%) | 17/30 (52) | 1/2 (50) | 0/2 | 0/3 | 18/37 (49) | NS‡ |
Creatine kinase, IU/L (range) |
1,345
(81–8,900) |
271
(128–414) |
92
(71–113) |
79
(57–102) |
1,119
(57–8,900) |
NS§ |
Complete blood count | ||||||
Leukocytosis, >10,000 leukocytes/μL, no. (%) | 15/33 (45) | 0/2 | 0/4 | 1/3 (33) | 16/42 (38) | NS‡ |
Leukopenia, <4,000 leukocytes/μL, no. (%) | 6/33 (18) | 1/2 (50) | 0/4 | 1/3 (33) | 8/42 (19) | NS‡ |
Leukocytes, × 103/μL, mean (range) | 14.2 (2.5–43.3) | 4.5 (2.6, 6.4) | 4.5 (4–5.2) | 10.2 (3.9–17.1) | 13.1 (2.5–43.3) | NS§ |
Lymphocytopenia, ALC <1,500/μL, no. (%) | 30/33 (91) | 2/2 (100) | 4/4 (100) | 3/3 (100) | 36/42 (93) | NS‡ |
ALC, × 103/μL, mean (range) | 0.9 (0.2–6.9) | 0.35 (0.3–0.4) | 1.26 (1.2–1.3) | 1.1 (0.6–2.3) | 0.9 (0.2–6.9) | NS§ |
Thrombocytopenia, platelets <150K cells/μL, no. (%) | 29/32 (88) | 2/2 (100) | 0/4 | 3/3 (100) | 34/41 (83) | 0.001‡ |
Platelets, × 103/μL, mean (range) |
84
(15–271) |
36
(26–46) |
238
(164–316) |
64
(37–101) |
82
(15–271) |
0.001§ |
Coagulopathy, INR >1.2, no. (%) | 16/33 (48) | 1/2 (50) | 0/2 | 0/3 | 17/40 (42) | NS‡ |
INR, mean (range) |
1.38
(0.9–3) |
1.5
(1.1–1.9) |
0.96
(0.93–1) |
1.09
(1.04–1.16) |
1.36 (0.9–3) |
NS§ |
Molecular diagnosis source, no. (%) | ||||||
Skin biopsy sample/eschar | 19 (58) | 1 (50) | 4 (100) | 3 (100) | 27 (64) | |
Blood | 16 (48) | 2 (100) | 0 | 1 (33) | 19 (45) | |
CSF | 1 (3) | 0 | 0 | 0 | 1 (2) | |
Other organs |
2 (6)¶ |
0 |
0 |
0 |
2 (5) |
|
Serologic diagnosis, no. (%) samples | 32 (97) | 2 (100) | 1 (25) | 1 (33) | 36 (86) | |
Positive | 5 (16) | 0 | 0 | 0 | 5 (14) | |
Borderline | 2 (6) | 0 | 0 | 1 (33) | 3 (8) | |
Negative | 25 (78) | 2 (100) | 1 (25) | 0 | 28 (78) |
*ALC, absolute lymphocyte count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CSF, cerebrospinal fluid; GGT, gamma glutamyl transpeptidase; INR, international normalized ratio; NS, not significant; ULN, within upper limit of normal range. †Highest or lowest levels reached within the time frame are reported. ‡By Pearson χ2 test. §By 1-way analysis of variance, conducted on day-of-admission data. ¶One from liver biopsy sample and 1 from enlarged lymph node.